Evaluation of Fab and F(ab′)2 fragments and isotype variants of a recombinant human monoclonal antibody against Shiga toxin 2

Infection and Immunity

Volumn 78, Issue 3, 2010, Pages 1376-1382

  Akiyoshi, Donna E ^a   Sheoran, Abhineet S ^a   Rich, Curtis M ^a   Richard, L ^a   Chapman Bonofiglio, Susan ^a   Tzipori, Saul ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 5C12; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG; VEROTOXIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CYTOTOXICITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTITOXINS; CELL SURVIVAL; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; HELA CELLS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MICE; POISONING; RECOMBINANT PROTEINS; SHIGA TOXIN 2; SURVIVAL ANALYSIS;

EID: 77349114882     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00867-09     Document Type: Article

References (35)

1. Akiyoshi, D. E., C. M. Rich, S. O'Sullivan-Murphy, L. Richard, J. Dilo, A. Donohue-Rolfe, A. S. Sheoran, S. Chapman-Bonofiglio, and S. Tzipori. 2005. Characterization of a human monoclonal antibody against Shiga toxin 2 expressed in Chinese hamster ovary cells. Infect. Immun. 73:4054-4061.
2. Andrew, S. M., and J. A. Titus. 2003. Fragmentation of immunoglobulin G. Curr. Protoc. Cell Biol. 16:16.4.
3. Bonifacino, J. S., and R. Rojas. 2006. Retrograde transport from endosomes to the trans-Golgi network. Nat. Rev. Mol. Cell Biol. 7:568-579.
4. Cherla, R. P., S. Y. Lee, and V. L. Tesh. 2003. Shiga toxins and apoptosis. FEMS Microbiol. Lett. 228:159-166.
5. Edwards, A. C., A. R. Melton-Celsa, K. Arbuthnott, J. R. Stinson, C. K. Schmitt, H. C. Wong, and A. O'Brien. 1998. Vero cell neutralization and mouse protective efficacy of humanized monoclonal antibodies against Escherichia coli toxins Stx1 and Stx2, p. 388-392. In J. B. Kasper and A. D. O'Brien (ed.), Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains. American Society for Microbiology, Washington, DC.
6. Gyles, C. L. 2007. Shiga toxin-producing Escherichia coli: an overview. J. Anim. Sci. 85:E45-E62.
7. Inoue, K., K. Itoh, H. Nakao, T. Takeda, and T. Suzuki. 2004. Characterization of a Shiga toxin 1-neutralizing recombinant Fab fragment isolated by phage display system. Tohoku J. Exp. Med. 203:295-303.
8. Kabat, E. A., T. T. Wu, H. M. Perry, K. S. Gottesman, and C. Foeller. 1992. Sequences of proteins of immunological interest, 5th ed. NIH publication no. 91-3242. U.S. Department of Health and Human Services, Public Health Service, NIH, Bethesda, MD.
9. Karch, H., P. I. Tarr, and M. Bielaszewska. 2005. Enterohaemorrhagic Escherichia coli in human medicine. Int. J. Med. Microbiol. 295:405-418.
10. Karmali, M. A. 2004. Infection by Shiga toxin-producing Escherichia coli: an overview. Mol. Biotechnol. 26:117-122.
11. Krautz-Peterson, G., S. Chapman-Bonofiglio, K. Boisvert, H. Feng, I. M. Herman, S. Tzipori, and A. S. Sheoran. 2008. Intracellular neutralization of Shiga toxin 2 by an A subunit-specific human monoclonal antibody. Infect. Immun. 76:1931-1939.
12. Ma, Y., X. Mao, J. Li, H. Li, Y. Feng, H. Chen, P. Luo, J. Gu, S. Yu, H. Zeng, G. Guo, K. Yang, and Q. Zou. 2008. Engineering an anti-Stx2 antibody to control severe infections of EHEC O157:H7. Immunol. Lett. 121:110-115.
13. Mukherjee, J., K. Chios, D. Fishwild, D. Hudson, S. O'Donnell, S. M. Rich, A. Donohue-Rolfe, and S. Tzipori. 2002. Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection. Infect. Immun. 70:612-619.
14. Mukherjee, J., K. Chios, D. Fishwild, D. Hudson, S. O'Donnell, S. M. Rich, A. Donohue-Rolfe, and S. Tzipori. 2002. Production and characterization of protective human antibodies against Shiga toxin 1. Infect. Immun. 70:5896-5899.
15. Mulvey, G., P. I. Kitov, P. Marcato, D. R. Bundle, and G. D. Armstrong. 2001. Glycan mimicry as a basis for novel anti-infective drugs. Biochimie 83:841-847.
16. Neri, P., S. I. Nagano, S. Yokoyama, H. Dohi, K. Kobayashi, T. Miura, T. Inazu, T. Sugiyama, Y. Nishida, and H. Mori. 2007. Neutralizing activity of polyvalent Gb3, Gb2 and galacto-trehalose models against Shiga toxins. Microbiol. Immunol. 51:581-592.
17. Nishikawa, K., K. Matsuoka, M. Watanabe, K. Igai, K. Hino, K. Hatano, A. Yamada, N. Abe, D. Terunuma, H. Kuzuhara, and Y. Natori. 2005. Identification of the optimal structure required for a Shiga toxin neutralizer with oriented carbohydrates to function in the circulation. J. Infect. Dis. 191:2097-2105.
18. O'Brien, A. D., and R. K. Holmes. 1987. Shiga and Shiga-like toxins. Microbiol. Rev. 51:206-220.
19. Paton, J. C., and A. W. Paton. 2006. Shiga toxin "goes retro" in human primary kidney cells. Kidney Int. 70:2049-2051.
20. Preston, M. J., A. A. Gerceker, M. E. Reff, and G. B. Pier. 1998. Production and characterization of a set of mouse-human chimeric immunoglobulin G (IgG) subclass and IgA monoclonal antibodies with identical variable regions specific for Pseudomonas aeruginosa serogroup O6 lipopolysaccharide. Infect. Immun. 66:4137-4142.
21. Saenz, J. B., T. A. Doggett, and D. B. Haslam. 2007. Identification and characterization of small molecules that inhibit intracellular toxin transport. Infect. Immun. 75:4552-4561.
22. Scheiring, J., S. P. Andreoli, and L. B. Zimmerhackl. 2008. Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS). Pediatr. Nephrol. 23:1749-1760.
23. Serna, A., IV, and E. C. Boedeker. 2008. Pathogenesis and treatment of Shiga toxin-producing Escherichia coli infections. Curr. Opin. Gastroenterol. 24:38-47.
24. Sheoran, A. S., S. Chapman, P. Singh, A. Donohue-Rolfe, and S. Tzipori. 2003. Stx2-specific human monoclonal antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variants. Infect. Immun. 71:3125-3130.
25. Sheoran, A. S., S. Chapman-Bonofiglio, B. R. Harvey, J. Mukherjee, G. Georgiou, A. Donohue-Rolfe, and S. Tzipori. 2005. Human antibody against Shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications. Infect. Immun. 73:4607-4613.
26. Siegler, R., and R. Oakes. 2005. Hemolytic uremic syndrome; pathogenesis, treatment, and outcome. Curr. Opin. Pediatr. 17:200-204.
27. Smith, M. J., A. R. Melton-Celsa, J. F. Sinclair, H. M. Carvalho, C. M. Robinson, and A. D. O'Brien. 2009. Monoclonal antibody 11E10 which neutralizes Shiga toxin type 2 (Stx2), recognizes three regions on the Stx2 A subunit, blocks the enzymatic action of the toxin in vitro, and alters the overall cellular distribution of the toxin. Infect. Immun. 77:2730-2740.
28. Tarr, P. I., C. A. Gordon, and W. L. Chandler. 2005. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365:1073-1086.
29. Tsuji, T., T. Shimizu, K. Sasaki, Y. Shimizu, K. Tsukamoto, H. Arimitsu, S. Ochi, S. Sugiyama, K. Taniguchi, P. Neri, and H. Mori. 2008. Protection of mice from Shiga toxin-2 toxemia by mucosal vaccine of Shiga toxin 2B-His with Escherichia coli enterotoxin. Vaccine 26:469-476.
30. Tsuji, T., T. Shimizu, K. Sasaki, K. Tsukamoto, H. Arimitsu, S. Ochi, K. Taniguchi, M. Noda, P. Neri, and H. Mori. 2008. A nasal vaccine comprising B-subunit derivative of Shiga toxin 2 for cross-protection against Shiga toxin types 1 and 2. Vaccine 26:2092-2099.
31. Tzipori, S., A. Sheoran, D. Akiyoshi, A. Donohue-Rolfe, and H. Trachtman. 2004. Antibody therapy in the management of Shiga toxin-induced hemolytic uremic syndrome. Clin. Microbiol. Rev. 17:926-941, table of contents.
32. Urlaub, G., and L. A. Chasin. 1980. Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity. Proc. Natl. Acad. Sci. U. S. A. 77:4216-4220.
33. Urlaub, G., P. J. Mitchell, E. Kas, L. A. Chasin, V. L. Funanage, T. T. Myoda, and J. Hamlin. 1986. Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions. Somat. Cell Mol. Genet. 12:555-566.
34. Wong, C. S., S. Jelacic, R. L. Habeeb, S. L. Watkins, and P. I. Tarr. 2000. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N. Engl. J. Med. 342:1930-1936.
35. Yamagami, S., M. Motoki, T. Kimura, H. Izumi, T. Takeda, Y. Katsuura, and Y. Matsumoto. 2001. Efficacy of postinfection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stx-producing Escherichia coli. J. Infect. Dis. 184:738-742.